Importantly, genetic ablation of Rspo1 robustly increases the thermogenic capacity of visceral fat and resists HFD‐induced obesity in vivo, indicating the underlying therapeutic potential to treat obesity by blocking RSPO1 signaling in adipose tissues (Figure S10C, Supporting Information). The gene discussed is RSPO1; the disease is Obesity.